E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
At least one focal liver lesion requiring further work-up for complete characterization. |
|
E.1.1.1 | Medical condition in easily understood language |
Subjects must have at least one liver lesion. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10024718 |
E.1.2 | Term | Liver tumor NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the sensitivity and specificity of Sonovue-enhanced
ultrasound is superior to that of unenhanced ultrasound for the
characterization of benign versus malignant focal liver lesions (FLLs)
using final diagnosis based on histology or combiend imaging (CE-CT
and/or CE-MRI)/clinical data as truth standard. |
|
E.2.2 | Secondary objectives of the trial |
1. to evaluate the accuracy and other performance parameters (positive
predictive value, negative predictive value of Sonovue-enhanced
ultrasound for characterization of benign versus malignant- FLLs in
comparison to unenhanced ultrasound
2. to evaluate the ability of Sonovue-enhanced ultrasound to obtain a
specific diagnosis of FLLs in comparison to unenhanced ultrasound.
3. to evaluate the inter-reader agreement in ultrasound images
assessment (unenhanced and Sonovue-enhanced separately)
4. to provide evidence of the safety and tolerability of intravenously
administered Sonovue in subjects with focal liver disease. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male/Female.
- Provides written Informed Consent and is willing to comply with
protocol requirements.
- Is at least 18 years of age.
- Has at least 1 FLL (target lesion) requiring work-up for characterization. Target lesion may include : Incidentally detected, in
subjects with chronic hepatitis or liver cirrhosis, in subjects with known
history of malignancy.
- Is scheduled for surgical removal or biopsy of the target lesion from
24h to 30 days after the Sonovue administration OR in case tissue biopsy is not indicated nor surgery planned, is scheduled for or has performed a CE-CT and/or CE-MRI of the target lesion from 30 days to 48h prior to or from 24h to 30 days after the administration of Sonovue. |
|
E.4 | Principal exclusion criteria |
-Has an acoustic window insufficient for adequate ultrasound
examination of the liver.
- Has a FLL that cannot be identified with unenhanced ultrasound.
- Has received or is scheduled for antineoplasic chemotherapy or an
invasive procedure in the time period between test procedures and truth standard assessments which may have modified the target lesion.
- Is receiving any other contrast medium, within the 48h before and up
to 24h following the administration of Sonovue.
- Known right to left cardiac shunt, bidirectional or transient.
- Has any allergy to 1 or more ingredients of the investigational product.
- Has received an investigational compound within 30 days before
admission into this study
- Has any contraindication to 1 of the planned imaging procedures
(implants, claustrophobia, etc.)
- Has any medical condition or other circumstances which would
significantly decrease the chances of obtaining reliable data, achieving
this study objectives, or completing the study and/or post-dose followup examinations.
- Is a pregnant or lactating female. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The sensitivity of Sonovue-enhanced ultrasound is superior as compared to unenhanced ultrasound for at least 2 of the 3 off-site assessors analyzing their data separately. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After clinical evaluation by 3 off-site assessors. |
|
E.5.2 | Secondary end point(s) |
The specificity of Sonovue-enhanced ultrasound is superior as compared to unenhanced ultrasound for at least 2 of the 3 off-site assessors analyzing their data separately. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After clinical evaluation by 3 off-site assessors. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
France |
Germany |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |